← back to search

Robert G. Uzzo

Case Comprehensive Cancer Center · US
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Renal and related cancers, and Prostate Cancer Diagnosis and Treatment.
h-index
93
citations
36,370
works
1,145
NIH funding
primary concept
Medicine
email

Recent publications

High Rate of Return to Sport for Athletes Undergoing Articular Cartilage Restoration Procedures for the Knee: A Systematic Review of Contemporary Studies
The American Journal of Sports Medicine 2025cited by 4position: middledoi
A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery.
2025cited by 1position: contributordoi
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
The Lancet Oncology 2024cited by 79position: middledoi
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
2024cited by 55position: contributordoi
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions
Nature Genetics 2024cited by 47position: middledoi
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
2024cited by 36position: contributordoi
Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma.
2024cited by 17position: contributordoi
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation.
2024cited by 11position: contributordoi
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
2024cited by 7position: contributordoi
Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.
2024cited by 5position: contributordoi
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010.
2024cited by 3position: contributordoi
Symptomatic and functional recovery after transurethral resection of bladder tumor: Data from ecological momentary symptom assessment.
2024cited by 3position: contributordoi
Targeting NPC1 in Renal Cell Carcinoma.
2024cited by 3position: contributordoi
Population Estimates of Ovarian Cancer Risk in a Cohort of Patients with Bladder Cancer.
2024cited by 3position: contributordoi
Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: a cohort analysis of over 3000 men.
2024cited by 3position: contributordoi
Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey.
2024cited by 3position: contributordoi
Transition to Value-based Healthcare: Development, Implementation, and Results of an Optimal Surgical Care Framework at a National Cancer Institute-designated Comprehensive Cancer Center.
2024cited by 2position: contributordoi
Real-time estimation of nephron activity with a linear measurement system (RENAL-MS) predicts postoperative estimated glomerular filtration rate.
2024cited by 2position: contributordoi
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.
2024cited by 2position: contributordoi
Genomic Evolution of Oligometastatic Clear Cell Renal Cell Carcinoma Presenting Two Decades Following Radical Nephrectomy.
2024cited by 1position: contributordoi
Supplementary Figure Legends from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
Supplementary Figure 8 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
Supplementary Figure 7 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
Supplementary Figure 6 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
Supplementary Figure 7 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
Supplementary Table 1 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
FIGURE 1 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
FIGURE 2 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
FIGURE 5 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi
Supplementary Figure 4 from Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Alexander Kutikov · Society of Surgical Oncology98 papers (2012–2024)Laura Bukavina · Elsevier, Inc.41 papers (2024–2024)Andres F. Correa · 41 papers (2024–2024)Elizabeth R. Plimack · The University of Texas Southwestern Medical Center41 papers (2020–2024)Henkel Valentine · Elsevier, Inc.40 papers (2024–2024)Daniel M. Geynisman · National Cancer Institute40 papers (2024–2024)Philip H. Abbosh · Bladder Cancer Advocacy Network40 papers (2024–2024)Mohit Sindhani · Indian Institute of Technology Delhi40 papers (2024–2024)Jason R. Brown · University Hospitals of Cleveland39 papers (2024–2024)Pooja Ghatalia · Cancer Research UK39 papers (2024–2024)Kirtishri Mishra · Elsevier, Inc.39 papers (2024–2024)Adam Calaway · Elsevier, Inc.39 papers (2024–2024)Mohammed Elshaer · American Society for Microbiology39 papers (2024–2024) · 39 papers (2024–2024)Mahmoud Ghannoum · Case Western Reserve University39 papers (2024–2024)Megan Prunty · Case Western Reserve University39 papers (2024–2024) · 39 papers (2024–2024) · 39 papers (2024–2024)Mohamed Eltoukhi · Case Western Reserve University39 papers (2024–2024)Mauricio Retuerto · 39 papers (2024–2024)